Week in Review: bioMérieux Acquires Majority Stake in China Diagnostics Company for $114 Million

Deals and Financings   bioMérieux, a French in vitro diagnostics company, paid $114 million to acquire a majority stake in Suzhou Hybiome Biomedical, also an immunoassay company; Ascendis Pharma of Denmark formed an $80 million China JV with Vivo Capital to develop its endocrinology rare disease therapies in Greater China; Shanghai 's Ocumension entered a $11.75 million deal for greater China rights to EyePoint Medical's medical device for long-term uveitis treatment; Zhejiang Jingxin Pharma invested a second $10 million in Mapi Pharma of Israel , which is developing treatments for schizophrenia and pain; Berry Genomics, a Beijing genomics testing company, will form a JV with Prenetics Limited to market direct-to-consumer genetic tests in China ; HuiyiHuiying of Beijing closed a funding round led by Intel Capital to develop its AI-based medical imaging program;  Trials and Approvals   Suzhou 's Innovent dosed the first patient in a China Phase III trial of its anti-PD-1 mAb in patients with squamous NSCLC; Company News   Ping An Good Doctor installed the first of its One-Minute Clinics, a freestanding booth that dispenses AI-based healthcare diagnosis and medicine without any employees on site; Government and Regulatory The Shanghai Stock Exchange will set up a New Board for innovative science and technology companies, although detailed IPO requirements have not been released. Stock Symbols: ( Paris : BIM) (NSDQ: ASND) (NSDQ: EYPT) (SHZ: 000710) (HKEX: 1801) (HK: 01833) Share this with colleagues: // //